# CARVYKTI (ciltacabtagene autoleucel) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/ciltacabtagene-autoleucel

> The FDA approved CARVYKTI (ciltacabtagene autoleucel), sponsored by JOHNSON & JOHNSON (JNJ), on February 28, 2022 for with relapsed or refractory multiple myeloma.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is CARVYKTI (ciltacabtagene autoleucel) FDA approved?

Yes. The FDA approved CARVYKTI (ciltacabtagene autoleucel), sponsored by JOHNSON & JOHNSON (JNJ), on February 28, 2022 for with relapsed or refractory multiple myeloma. SEC Form 10-K: "On February 28, 2022, the FDA approved our product CARVYKTI (cilta-cel) for the treatment of adults with RRMM who have received four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody." [Calendar and source filings](https://sec-api.dev/pdufa/ciltacabtagene-autoleucel)

Source: SEC Form 10-K, accession 0001801198-25-000012, https://www.sec.gov/Archives/edgar/data/1801198/000180119825000012/legn-20241231.htm (retrieved 2026-11-12). Last confirmed 2025-12-08. Cite: https://sec-api.dev/pdufa/ciltacabtagene-autoleucel#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | CARVYKTI (ciltacabtagene autoleucel) |
| Codes |  |
| Sponsor | JOHNSON & JOHNSON (JNJ) https://sec-api.dev/companies/jnj/catalysts |
| Indications | [with relapsed or refractory multiple myeloma](https://sec-api.dev/indications/with-relapsed-or-refractory-multiple-myeloma), with rrmm |
| Modality | cell_therapy |
| FDA designations | none disclosed |

## Timeline

### February 28, 2022: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: with relapsed or refractory multiple myeloma.
- First seen 2024-12-10, last confirmed 2025-12-08.
- Press release filed with the SEC (EX-99) (accession 0001171843-25-007796): "In February 2022, cilta-cel was approved by the U.S. Food and Drug Administration (FDA) under the brand name CARVYKTI® for the treatment of adults with relapsed or refractory multiple myeloma." https://www.sec.gov/Archives/edgar/data/1801198/000117184325007796/exh_991.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-25-006904): "In February 2022, cilta-cel was approved by the U.S. Food and Drug Administration (FDA) under the brand name CARVYKTI® for the treatment of adults with relapsed or refractory multiple myeloma." https://www.sec.gov/Archives/edgar/data/1801198/000117184325006904/exh_991.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-25-003621): "In February 2022, cilta-cel was approved by the U.S. Food and Drug Administration (FDA) under the brand name CARVYKTI® for the treatment of adults with relapsed or refractory multiple myeloma." https://www.sec.gov/Archives/edgar/data/1801198/000117184325003621/exh_991.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-25-003412): "In February 2022, cilta-cel was approved by the U.S. Food and Drug Administration (FDA) under the brand name CARVYKTI® for the treatment of adults with relapsed or refractory multiple myeloma." https://www.sec.gov/Archives/edgar/data/1801198/000117184325003412/exh_991.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-24-006838): "In February 2022, cilta-cel was approved by the U.S. Food and Drug Administration (FDA) under the brand name CARVYKTI® for the treatment of adults with relapsed or refractory multiple myeloma." https://www.sec.gov/Archives/edgar/data/1801198/000117184324006838/exh_991.htm
- SEC Form 10-K (accession 0001801198-25-000012): "On February 28, 2022, the FDA approved our product CARVYKTI (cilta-cel) for the treatment of adults with RRMM who have received four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody." https://www.sec.gov/Archives/edgar/data/1801198/000180119825000012/legn-20241231.htm

### March 15, 2024: FDA advisory committee meeting

- Status: completed, positive. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA advisory committee calendar: "During the morning session, the Committee will discuss supplemental biologics license application (sBLA) 125746.74 for CARVYKTI (ciltacabtagene autoleucel), suspension for intravenous infusion, submitted by Janssen Biotech, Inc. The proposed indication for this product is for the treatment of adult patients with relapsed or refractory multiple myeloma, who have received at least one prior line of therapy, including a proteasome inhibitor, and an immunomodulatory agent, and are refractory to lenalidomide." https://www.fda.gov/advisory-committees/advisory-committee-calendar/march-15-2024-meeting-oncologic-drugs-advisory-committee-meeting-announcement-03152024
- FDA advisory committee calendar: "VOTE: Is the risk-benefit assessment for ciltacabtagene autoleucel for the proposed indication, favorable? Vote Result: Yes: 11 No: 0 Abstain: 0" https://www.fda.gov/media/178184/download

## Same indication

- [TECVAYLI (teclistamab)](https://sec-api.dev/pdufa/teclistamab) (JNJ)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/ciltacabtagene-autoleucel.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "CARVYKTI (ciltacabtagene autoleucel) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/ciltacabtagene-autoleucel

```bibtex
@misc{secapidev_pdufa_ciltacabtagene_autoleucel_20261116,
  title        = {CARVYKTI (ciltacabtagene autoleucel) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/ciltacabtagene-autoleucel}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_ciltacabtagene_autoleucel_20261116","title":"CARVYKTI (ciltacabtagene autoleucel) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/ciltacabtagene-autoleucel","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
